Breast Cancer Clinical Trials in Houston

Showing 241-260 of 575 trials

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

TNBC - Triple-Negative Breast CancerMinimal Residual Disease

Personalis Inc.422 participantsStarted Nov 2023

Tucson, Arizona, United States • Aurora, Colorado, United States • Washington D.C., District of Columbia, United States +11 more locations

TERMINATEDPhase 1/2< 1 mile

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

CancerSolid TumorSolid Carcinoma+17 more

Aminex Therapeutics, Inc.15 participantsStarted Nov 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +4 more locations

CtDNA Based MRD Testing for NAC Monitoring in TNBC

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Breast Cancer Trials in Other Cities

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2

Comprehensive Outcomes for After Cancer Health

FPA150 in Patients With Advanced Solid Tumors

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Milademetan in Advanced/Metastatic Solid Tumors

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Other Conditions in Houston